The global next generation sequencing was valued at $6,598.62 million in 2020, and is projected to reach $35,503.66 million by 2030, registering a CAGR of 18.2% from 2021 to 2030.
Next generation sequencing (NGS) is a novel procedure for sequencing genomes at low costs and high speed with improved efficiency. NGS, also known as deep sequencing and parallel sequencing, is a technology that has revolutionized molecular biology and genomics research. It is a high throughput, non-Sanger based sequencing method. Next generation sequencing has made sequencing of genomes very rapid and cost-effective. Through this method, billions of DNA strands can be sequenced efficiently. Next generation sequencing has made it possible to conveniently sequence whole genomes and analyze various DNA-protein interactions. This technique allows the researcher to focus, study, and interpret deep sequence target regions. Next generation sequencing can be utilized through varied interventions such as oncology, biomarker studies, drug discovery, understanding reproductive health, and personalized genomics.
The impact of COVID-19 pandemic is expected to remain positive for the next generation sequencing industry. As next generation sequencing plays crucial and essential role in clinical labs and research to fight against COVID-19 pandemic. To fight against COVID -19 pandemic researchers and scientists together way to identify the new strain of corona virus without any prior knowledge organisms. A huge number of researches were conducted on DNA and RNA of corona virus to understand how it enters human cells and to learn about its pathogenesis.
For instance, in June 2020, U.S. Food and Drug Administration announced the emergency use authorization (EUA) to Illumina, Inc., for first COVID-19 diagnostic test by using next generation sequence technology. In addition, in June 2021, Thermo Fisher Scientific, a global leader in serving science, launched Ion AmpliSeq SARS-CoV-2 insight research assay which enable the researcher to identify the COVID-19 variants with rapid turnaround time. Subsequently, this leads to increase in demand for next generation sequencing technology in any biotechnology & pharma companies, universities, and laboratories.
The growth of the global next generation sequencing testing market is majorly driven by technological advancements in sequencing platforms, surge in applications of next generation sequencing, and increase in genome mapping programs. For instance, in August 2020, Ancestry, a genomic company, launched Ancestry Health powered by Next Generation Sequencing tool which helps for screening the gene which is associated with breast cancer, blood disorders and colon cancer. Moreover, in 2021, National Institute of Oceanography (NIO) announced the first-of-its-kind project of genomic mapping in India. It aims to understand the biochemistry and the response of ocean to environmental pollution, nutrient stress, and climatic change by conducting the genomic mapping of microorganism. In addition, rise in awareness pertaining to next generation sequencing and rise in investment in research, development, and innovation, supplement the market growth. In addition, in 2020, Thermo Fisher Scientific, an American provisioner leading company in serving science, invested $1.2 billion in R&D in order to develop novel technologies.
However, lack of skilled professionals, ethical & legal limitation related to next generation sequencing, and standardization concerns in sequencing procedures impede the market growth. Furthermore, use of cloud computing as a potential data management service and untapped emerging economies offer lucrative opportunities for the market players.
Next generation sequencing market is segmented on the basis of product type, application, technology and end user. By product, the market is classified into consumables, platforms, and services. The consumables product segment is further classified based on sample preparation consumables and other consumables. The sample preparation consumables are further segmented into DNA fragmentation, end repair, A-Tailing & size selection, library preparation & target enrichment, and quality control. The platform NGS product segment is segmented into HiSeq, MiSeq, Ion Torrent, SOLiD, Pacbio Rs II & Sequel System, and other sequencing platforms. The services segment is divided into sequencing services and data management. By application, this market is divided into biomarkers & cancer, diagnostics, reproductive health, personalized medicine, agriculture & animal research, and other applications. By technology, the next generation sequencing technology market is classified into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing, and other technologies. On the basis of end user, the market is classified into academic & research centers, pharmaceutical and biotechnology companies, hospital & clinics and other end user. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the key players operating in the global next generation sequencing market include Illumine, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., Beijing Genomics Institute, Qiagen N.V., 454 Life Sciences Corporation (Roche Holding AG), Agilent Technologies, Inc. PerkinElmer, Inc., Genomatix GmbH, and PierianDx., Eurofins Scientific, Gatc Biotech AG, Macrogen, Inc., Oxford Nanopore Technologies, Ltd., Bio-Rad Laboratories, Inc.
Next generation sequencing (NGS) is a novel procedure for sequencing genomes at low costs and high speed with improved efficiency. NGS, also known as deep sequencing and parallel sequencing, is a technology that has revolutionized molecular biology and genomics research. It is a high throughput, non-Sanger based sequencing method. Next generation sequencing has made sequencing of genomes very rapid and cost-effective. Through this method, billions of DNA strands can be sequenced efficiently. Next generation sequencing has made it possible to conveniently sequence whole genomes and analyze various DNA-protein interactions. This technique allows the researcher to focus, study, and interpret deep sequence target regions. Next generation sequencing can be utilized through varied interventions such as oncology, biomarker studies, drug discovery, understanding reproductive health, and personalized genomics.
The impact of COVID-19 pandemic is expected to remain positive for the next generation sequencing industry. As next generation sequencing plays crucial and essential role in clinical labs and research to fight against COVID-19 pandemic. To fight against COVID -19 pandemic researchers and scientists together way to identify the new strain of corona virus without any prior knowledge organisms. A huge number of researches were conducted on DNA and RNA of corona virus to understand how it enters human cells and to learn about its pathogenesis.
For instance, in June 2020, U.S. Food and Drug Administration announced the emergency use authorization (EUA) to Illumina, Inc., for first COVID-19 diagnostic test by using next generation sequence technology. In addition, in June 2021, Thermo Fisher Scientific, a global leader in serving science, launched Ion AmpliSeq SARS-CoV-2 insight research assay which enable the researcher to identify the COVID-19 variants with rapid turnaround time. Subsequently, this leads to increase in demand for next generation sequencing technology in any biotechnology & pharma companies, universities, and laboratories.
The growth of the global next generation sequencing testing market is majorly driven by technological advancements in sequencing platforms, surge in applications of next generation sequencing, and increase in genome mapping programs. For instance, in August 2020, Ancestry, a genomic company, launched Ancestry Health powered by Next Generation Sequencing tool which helps for screening the gene which is associated with breast cancer, blood disorders and colon cancer. Moreover, in 2021, National Institute of Oceanography (NIO) announced the first-of-its-kind project of genomic mapping in India. It aims to understand the biochemistry and the response of ocean to environmental pollution, nutrient stress, and climatic change by conducting the genomic mapping of microorganism. In addition, rise in awareness pertaining to next generation sequencing and rise in investment in research, development, and innovation, supplement the market growth. In addition, in 2020, Thermo Fisher Scientific, an American provisioner leading company in serving science, invested $1.2 billion in R&D in order to develop novel technologies.
However, lack of skilled professionals, ethical & legal limitation related to next generation sequencing, and standardization concerns in sequencing procedures impede the market growth. Furthermore, use of cloud computing as a potential data management service and untapped emerging economies offer lucrative opportunities for the market players.
Next generation sequencing market is segmented on the basis of product type, application, technology and end user. By product, the market is classified into consumables, platforms, and services. The consumables product segment is further classified based on sample preparation consumables and other consumables. The sample preparation consumables are further segmented into DNA fragmentation, end repair, A-Tailing & size selection, library preparation & target enrichment, and quality control. The platform NGS product segment is segmented into HiSeq, MiSeq, Ion Torrent, SOLiD, Pacbio Rs II & Sequel System, and other sequencing platforms. The services segment is divided into sequencing services and data management. By application, this market is divided into biomarkers & cancer, diagnostics, reproductive health, personalized medicine, agriculture & animal research, and other applications. By technology, the next generation sequencing technology market is classified into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing, and other technologies. On the basis of end user, the market is classified into academic & research centers, pharmaceutical and biotechnology companies, hospital & clinics and other end user. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the key players operating in the global next generation sequencing market include Illumine, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., Beijing Genomics Institute, Qiagen N.V., 454 Life Sciences Corporation (Roche Holding AG), Agilent Technologies, Inc. PerkinElmer, Inc., Genomatix GmbH, and PierianDx., Eurofins Scientific, Gatc Biotech AG, Macrogen, Inc., Oxford Nanopore Technologies, Ltd., Bio-Rad Laboratories, Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global next generation sequencing market trends from 2020 to 2030 to identify the prevailing opportunities along with the strategic assessment.
- The next generation sequencing market forecast is studied from 2020 to 2030.
- The market size and estimations are based on a comprehensive analysis of key developments in the next generation sequencing industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the next generation sequencing market.
KEY MARKET SEGMENTS
By Product Type
- Consumables
- Sample Preparation Consumables
- DNA Fragmentation, End Repair, A-Tailing and Size Selection
- Library Preparation & Target Enrichment
- Quality Control
- Other Consumables
- Platforms
- HiSeq
- MiSeq
- Ion Torrent
- SOLiD
- Pacbio Rs II and Sequel System
- Other Sequencing Platforms
- Services
- Sequencing Services
- RNA Sequencing
- Whole Exome Sequencing
- Whole Genome Sequencing
- Targeted Sequencing
- Chip Sequencing
- De Novo Sequencing
- Methyl Sequencing
- Data Management Services
- NGS Data Analysis Services
- NGS Data Analysis Software & Workbenches
- NGS Storage, Management and Cloud Computing Solutions
By Application
- Diagnostics
- Biomarkers and Cancer
- Reproductive Health
- Personalized Medicine
- Agriculture and Animal Research
- Other Applications
By Technology
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- Sequencing by Ligation
- Pyrosequencing
- Single Molecule Real Time Sequencing
- Other Technologies
By End User
- Academic and Research Centers
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Other End Users
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Taiwan
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Illumine, Inc.,
- Thermo Fisher Scientific, Inc.,
- Pacific Biosciences of California, Inc.,
- Beijing Genomics Institute,
- Qiagen N.V.,
- Life Sciences Corporation (Roche Holding AG),
- Agilent Technologies, Inc.
- PerkinElmer, Inc.,
- Genomatix GmbH,
- Pierian Dx
List of other players in the value chain (profiles not included in the report):
- Eurofins Scientific
- Gatc Biotech AG
- Macrogen, Inc.
- Oxford Nanopore Technologies, Ltd.
- Bio-Rad Laboratories, Inc.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Technological advancements in NGS
3.5.1.2. Surge in applications of NGS
3.5.1.3. Increase in partnerships and collaborations strategies
3.5.1.4. Increase in demand for genome mapping programs
3.5.2. Restraint
3.5.2.1. Standardization concerns over NGS-based diagnostics
3.5.2.2. Lack of skilled professionals
3.5.2.3. Ethical and legal limitations
3.5.3. Opportunity
3.5.3.1. Lucrative opportunities in key market players
3.5.3.2. Surge in demand for Cloud computing, a potential data management service
3.5.4. Impact analysis
3.6. Impact analysis of COVID-19 on the next generation sequencing (NGS) market
CHAPTER 4: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Consumables
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Sample preparation consumables
4.2.2.1.1. Market size and forecast, by type
4.2.2.1.1.1. DNA Fragmentation, End Repair, A-Tailing, and Size Selection
4.2.2.1.1.2. Library preparation & target enrichment
4.2.2.1.1.3. Quality Control
4.2.2.2. Other Consumables
4.2.2.2.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis by country
4.3. Platforms
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. HiSeq series
4.3.2.1.1. Market size and forecast
4.3.2.2. MiSeq series
4.3.2.2.1. Market size and forecast
4.3.2.3. ION Torrent
4.3.2.3.1. Market size and forecast
4.3.2.4. SOLiD
4.3.2.4.1. Market size and forecast
4.3.2.5. Pacbio Rs II and Sequel systems
4.3.2.5.1. Market size and forecast
4.3.2.6. Other Sequencing Platforms
4.3.2.6.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
4.4. Services
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by type
4.4.2.1. Sequencing Services
4.4.2.1.1. Market size and forecast, by type
4.4.2.1.1.1. RNA Sequencing
4.4.2.1.1.2. Whole exome sequencing
4.4.2.1.1.3. Whole genome sequencing
4.4.2.1.1.4. Targeted sequencing
4.4.2.1.1.5. Chip sequencing
4.4.2.1.1.6. De Novo sequencing
4.4.2.1.1.7. Methyl sequencing
4.4.2.2. Data management services
4.4.2.2.1. Market size and forecast, by type
4.4.2.2.1.1. NGS Data Analysis Services
4.4.2.2.1.2. NGS data analysis software & workbenches
4.4.2.2.1.3. NGS storage, management, and cloud computing solutions
4.4.3. Market size and forecast, by region
4.4.4. Market analysis by country
CHAPTER 5: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION
5.1. Overview
5.2. Market size and forecast
5.3. Biomarkers and cancer
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Diagnostics
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Reproductive health
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Personalized medicine
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Agriculture and animal research
5.7.1. Market size and forecast, by region
5.7.2. Market analysis by country
5.8. Other applications
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country
CHAPTER 6: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY
6.1. Overview
6.2. Market size and forecast
6.3. Sequencing by synthesis (SBS)
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Ion semiconductor sequencing (IOS)
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
6.5. Sequencing by Ligation (SBL)
6.5.1. Market size and forecast, by region
6.5.2. Market analysis, by country
6.6. Pyrosequencing
6.6.1. Market size and forecast, by region
6.6.2. Market analysis, by country
6.7. Single-molecule-real-time sequencing (SMRT)
6.7.1. Market size and forecast, by region
6.7.2. Market analysis, by country
6.8. Other technologies
6.8.1. Market size and forecast, by region
6.8.2. Market analysis, by country
CHAPTER 7: NEXT-GENERATION SEQUENCING MARKET, BY END USER
7.1. Overview
7.2. Market size and forecast
7.3. Academic & clinical research centers
7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country
7.4. Pharmaceutical & biotechnology companies
7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country
7.5. Hospitals & clinics
7.5.1. Market size and forecast, by region
7.5.2. Market analysis, by country
7.6. Other end users
7.6.1. Market size and forecast, by region
7.6.2. Market analysis, by country
CHAPTER 8: NEXT-GENERATION SEQUENCING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends and opportunities
8.2.2. North America next-generation sequencing market, by country
8.2.2.1. U. S.
8.2.2.1.1. U. S. next-generation sequencing market, by product
8.2.2.1.2. U. S. next-generation sequencing market, by application
8.2.2.1.3. U. S. next-generation sequencing market, by technology
8.2.2.1.4. U. S. next-generation sequencing market, by end user
8.2.2.2. Canada
8.2.2.2.1. Canada next-generation sequencing market, by product
8.2.2.2.2. Canada next-generation sequencing market, by application
8.2.2.2.3. Canada next-generation sequencing market, by technology
8.2.2.2.4. Canada next-generation sequencing market, by end user
8.2.2.3. Mexico
8.2.2.3.1. Mexico next-generation sequencing market, by product
8.2.2.3.2. Mexico next-generation sequencing market, by application
8.2.2.3.3. Mexico next-generation sequencing market, by technology
8.2.2.3.4. Mexico next-generation sequencing market, by end user
8.2.3. North America next-generation sequencing market, by product
8.2.4. North America next-generation sequencing market, by application
8.2.5. North America next-generation sequencing market, by technology
8.2.6. North America next-generation sequencing market, by end user
8.3. Europe
8.3.1. Key market trends and opportunities
8.3.2. Europe next-generation sequencing market, by country
8.3.2.1. Germany next-generation sequencing market, by product
8.3.2.2. Germany
8.3.2.2.1. Germany next-generation sequencing market, by application
8.3.2.2.2. Germany next-generation sequencing market, by technology
8.3.2.2.3. Germany next-generation sequencing market, by end user
8.3.2.3. France
8.3.2.3.1. France next-generation sequencing market, by product
8.3.2.3.2. France next-generation sequencing market, by application
8.3.2.3.3. France next-generation sequencing market, by technology
8.3.2.3.4. France next-generation sequencing market, by end user
8.3.2.4. Italy
8.3.2.4.1. Italy next-generation sequencing market, by product
8.3.2.4.2. Italy next-generation sequencing market, by application
8.3.2.4.3. Italy next-generation sequencing market, by technology
8.3.2.4.4. Italy next-generation sequencing market, by end user
8.3.2.5. UK
8.3.2.5.1. UK next-generation sequencing market, by product
8.3.2.5.2. UK next-generation sequencing market, by application
8.3.2.5.3. UK next-generation sequencing market, by technology
8.3.2.5.4. UK next-generation sequencing market, by end user
8.3.2.6. Spain
8.3.2.6.1. Spain next-generation sequencing market, by product
8.3.2.6.2. Spain next-generation sequencing market, by application
8.3.2.6.3. Spain next-generation sequencing market, by technology
8.3.2.6.4. Spain next-generation sequencing market, by end user
8.3.2.7. Rest of Europe
8.3.2.7.1. Rest of Europe next-generation sequencing market, by product
8.3.2.7.2. Rest of Europe next-generation sequencing market, by application
8.3.2.7.3. Rest of Europe next-generation sequencing market, by technology
8.3.2.7.4. Rest of Europe next-generation sequencing market, by end user
8.3.3. Europe next-generation sequencing market, by product
8.3.4. Europe next-generation sequencing market, by application
8.3.5. Europe next-generation sequencing market, by technology
8.3.6. Europe next-generation sequencing market, by end user
8.4. Asia-Pacific
8.4.1. Key market trends and opportunities
8.4.2. Asia-Pacific next-generation sequencing market, by country
8.4.2.1. Australia
8.4.2.1.1. Australia next-generation sequencing market, by product
8.4.2.1.2. Australia next-generation sequencing market, by application
8.4.2.1.3. Australia next-generation sequencing market, by technology
8.4.2.1.4. Australia next-generation sequencing market, by end user
8.4.2.2. Japan
8.4.2.2.1. Japan next-generation sequencing market, by product
8.4.2.2.2. Japan next-generation sequencing market, by application
8.4.2.2.3. Japan next-generation sequencing market, by technology
8.4.2.2.4. Japan next-generation sequencing market, by end user
8.4.2.3. India
8.4.2.3.1. India next-generation sequencing market, by product
8.4.2.3.2. India next-generation sequencing market, by application
8.4.2.3.3. India next-generation sequencing market, by technology
8.4.2.3.4. India next-generation sequencing market, by end user
8.4.2.4. China
8.4.2.4.1. China next-generation sequencing market, by product
8.4.2.4.2. China next-generation sequencing market, by application
8.4.2.4.3. China next-generation sequencing market, by technology
8.4.2.4.4. China next-generation sequencing market, by end user
8.4.2.5. South Korea
8.4.2.5.1. South Korea next-generation sequencing market, by product
8.4.2.5.2. South Korea next-generation sequencing market, by application
8.4.2.5.3. South Korea next-generation sequencing market, by technology
8.4.2.5.4. South Korea next-generation sequencing market, by end user
8.4.2.6. Taiwan
8.4.2.6.1. Taiwan next-generation sequencing market, by product
8.4.2.6.2. Taiwan next-generation sequencing market, by application
8.4.2.6.3. Taiwan next-generation sequencing market, by technology
8.4.2.6.4. Taiwan next-generation sequencing market, by end user
8.4.2.7. Rest of Asia-Pacific
8.4.2.7.1. Rest of Asia-Pacific next-generation sequencing market, by product
8.4.2.7.2. Rest of Asia-Pacific next-generation sequencing market,by application
8.4.2.7.3. Rest of Asia-Pacific next-generation sequencing market, by technology
8.4.2.7.4. Rest of Asia-Pacific next-generation sequencing market, by end user
8.4.3. Asia-Pacific next-generation sequencing market, by product
8.4.4. Asia-Pacific next-generation sequencing market, by application
8.4.5. Asia-Pacific next-generation sequencing market, by technology
8.4.6. Asia-Pacific next-generation sequencing market, by end user
8.5. LAMEA
8.5.1. Key market trends and opportunities
8.5.2. LAMEA next-generation sequencing market, by country
8.5.2.1. Brazil
8.5.2.1.1. Brazil next-generation sequencing market, by product
8.5.2.1.2. Brazil next-generation sequencing market, by application
8.5.2.1.3. Brazil next-generation sequencing market, by technology
8.5.2.1.4. Brazil next-generation sequencing market, by end user
8.5.2.2. Turkey
8.5.2.2.1. Turkey next-generation sequencing market, by product
8.5.2.2.2. Turkey next-generation sequencing market, by application
8.5.2.2.3. Turkey next-generation sequencing market, by technology
8.5.2.2.4. Turkey next-generation sequencing market, by end user
8.5.2.3. Saudi Arabia
8.5.2.3.1. Saudi Arabia next-generation sequencing market, by product
8.5.2.3.2. Saudi Arabia next-generation sequencing market, by application
8.5.2.3.3. Saudi Arabia next-generation sequencing market, by technology
8.5.2.3.4. Saudi Arabia next-generation sequencing market, by end user
8.5.2.4. South Africa
8.5.2.4.1. South Africa next-generation sequencing market, by product
8.5.2.4.2. South Africa next-generation sequencing market, by application
8.5.2.4.3. South Africa next-generation sequencing market, by technology
8.5.2.4.4. South Africa next-generation sequencing market, by end user
8.5.2.5. Rest of LAMEA
8.5.2.5.1. Rest of LAMEA next-generation sequencing market, by product
8.5.2.5.2. Rest of LAMEA next-generation sequencing market, by application
8.5.2.5.3. Rest of LAMEA next-generation sequencing market, by technology
8.5.2.5.4. Rest of LAMEA next-generation sequencing market, by end user
8.5.3. LAMEA next-generation sequencing market, by product
8.5.4. LAMEA next-generation sequencing market, by application
8.5.5. LAMEA next-generation sequencing market, by technology
8.5.6. LAMEA next-generation sequencing market, by end user
CHAPTER 9: COMPANY PROFILES
9.1. AGILENT TECHNOLOGIES, INC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments
9.2. BGI GROUP
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Key strategic moves and developments
9.3. F. HOFFMANN-LA ROCHE AG
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. ILLUMINA INC.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.4.6. Key strategic moves and developments
9.5. PRECIGEN INC., (INTREXON BIOINFORMATICS GERMANY GMBH)
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments
9.7. PERKINELMER, INC.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments
9.8. PIERIANDX INC.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Key strategic moves and developments
9.9. QIAGEN N. V.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. THERMO FISHER SCIENTIFIC INC.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developmentsLIST OF TABLES
TABLE 01. GLOBAL NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 02. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR CONSUMABLES, BY TYPE 2020-2030 ($MILLION)
TABLE 03. SAMPLE PREPARATION CONSUMABLES MARKET REVENUE, BY TYPE, 2020-2030 ($MILLION)
TABLE 04. DNA FRAGMENTATION, END REPAIR, A-TAILING & SIZE SELECTION: KEY PRODUCTS
TABLE 05. LIBRARY PREPARATION & TARGET ENRICHMENT: KEY PRODUCTS
TABLE 06. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR CONSUMABLES, BY REGION
2020-2030($MILLION)
TABLE 07. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR PLATFORMS, BY TYPE 2020-2030 ($MILLION)
TABLE 08. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR PLATFORM, BY REGION
2020-2030($MILLION)
TABLE 09. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SERVICES, BY TYPE 2020-2030 ($MILLION)
TABLE 10. SEQUENCING SERVICES MARKET REVENUE, BY TYPE, 2020-2030 ($MILLION)
TABLE 11. SEQUENCING SERVICES MARKET REVENUE, BY TYPE, 2020-2030 ($MILLION)
TABLE 12. NGS DATA ANALYSIS SOFTWARE & WORKBENCHES: KEY PRODUCTS
TABLE 13. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SERVICES, BY REGION 2020-2030($MILLION)
TABLE 14. GLOBAL NEXT-GENERATION SEQUENCING MARKET REVENUE, BY APPLICATION, 2018-2026 ($MILLION)
TABLE 15. NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR
BIOMARKERS AND CANCER, BY REGION 2020-2030($MILLION)
TABLE 16. NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR
DIAGNOSTICS, BY REGION 2020-2030 ($MILLION)
TABLE 17. NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR REPRODUCTIVE HEALTH, BY REGION 2020-2030($MILLION)
TABLE 18. NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR PERSONALIZED MEDICINE, BY REGION 2020-2030 ($MILLION)
TABLE 19. NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR
AGRICULTURE AND ANIMAL RESEARCH, BY REGION 2020-2030($MILLION)
TABLE 20. NEXT-GENERATION SEQUENCING MARKET REVENUE OF NEXT-GENERATION SEQUENCING FOR
OTHER APPLICATIONS, BY REGION 2020-2030 ($MILLION)
TABLE 21. GLOBAL NEXT-GENERATION SEQUENCING MARKET REVENUE, BY TECHNOLOGY, 2018-2026 ($MILLION)
TABLE 22. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SEQUENCING BY SYNTHESIS, BY REGION
2020-2030 ($MILLION)
TABLE 23. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR ION SEMICONDUCTOR SEQUENCING,
BY REGION 2020-2030 ($MILLION)
TABLE 24. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SEQUENCING BY LIGATION, BY REGION
2020-2030 ($MILLION)
TABLE 25. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR PYROSEQUENCING, BY REGION 2020-2030 ($MILLION)
TABLE 26. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR SINGLE-MOLECULE-REAL-TIME SEQUENCING,
BY REGION 2020-2030($MILLION)
TABLE 27. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR OTHER APPLICATIONS, BY REGION
2020-2030 ($MILLION)
TABLE 28. GLOBAL NEXT-GENERATION SEQUENCING MARKET REVENUE, BY END USER, 2020-2030 ($MILLION)
TABLE 29. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR ACADEMIC & CLINICAL RESEARCH CENTERS,
BY REGION 2020-2030 ($MILLION)
TABLE 30. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2030 ($MILLION)
TABLE 31. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR HOSPITALS & CLINICS, BY REGION,
2020-2030 ($MILLION)
TABLE 32. NEXT-GENERATION SEQUENCING MARKET REVENUE FOR OTHER END USERS, BY REGION,
2020-2030 ($MILLION)
TABLE 33. NEXT-GENERATION SEQUENCING MARKET REVENUE, BY REGION, 2020-2030 ($MILLION)
TABLE 34. NORTH AMERICA NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 35. U.S. NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 36. U.S. NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 37. U.S. NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 38. U.S. NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 39. CANADA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 40. CANADA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 41. CANADA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 42. CANADA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43. MEXICO NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 44. MEXICO NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 45. MEXICO NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 46. MEXICO NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 47. NORTH AMERICA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 48. NORTH AMERICA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 49. NORTH AMERICA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 50. NORTH AMERICA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 51. EUROPE NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 52. GERMANY NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 53. GERMANY NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 54. GERMANY NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 55. GERMANY NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 56. FRANCE NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 57. FRANCE NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 58. FRANCE NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 59. FRANCE NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 60. ITALY NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 61. ITALY NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 62. ITALY NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 63. ITALY NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 64. UK NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 65. UK NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 66. UK NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 67. UK NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 68. SPAIN NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 69. SPAIN NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 70. SPAIN NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 71. SPAIN NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 72. REST OF EUROPE NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 73. REST OF EUROPE NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 74. REST OF EUROPE NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 75. REST OF EUROPE NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 76. EUROPE NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 77. EUROPE NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 78. EUROPE NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 79. EUROPE NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 80. ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 81. AUSTRALIA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 82. AUSTRALIA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 83. AUSTRALIA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 84. AUSTRALIA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 85. JAPAN NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 86. JAPAN NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 87. JAPAN NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 88. JAPAN NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 89. INDIA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 90. INDIA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 91. INDIA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 92. INDIA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 93. CHINA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 94. CHINA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 95. CHINA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 96. CHINA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 97. SOUTH KOREA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 98. SOUTH KOREA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 99. SOUTH KOREA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 100. SOUTH KOREA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 101. TAIWAN NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 102. TAIWAN NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 103. TAIWAN NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 104. TAIWAN NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 105. REST OF ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT,
2020-2030 ($MILLION)
TABLE 106. REST OF ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION,
2020-2030 ($MILLION)
TABLE 107. REST OF ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY,
2020-2030 ($MILLION)
TABLE 108. REST OF ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY END USER,
2020-2030 ($MILLION)
TABLE 109. ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 110. ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 111. ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 112. ASIA-PACIFIC NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 113. LAMEA NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 114. BRAZIL NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 115. BRAZIL NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 116. BRAZIL NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 117. BRAZIL NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 118. TURKEY NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 119. TURKEY NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 120. TURKEY NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 121. TURKEY NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 122. SAUDI ARABIA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 123. SAUDI ARABIA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 124. SAUDI ARABIA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 125. SAUDI ARABIA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 126. SOUTH AFRICA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 127. SOUTH AFRICA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 128. SOUTH AFRICA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 129. SOUTH AFRICA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 130. REST OF LAMEA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 131. REST OF LAMEA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 132. REST OF LAMEA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 133. REST OF LAMEA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 134. LAMEA NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 135. LAMEA NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 136. LAMEA NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 137. LAMEA NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 138. AGILENT: COMPANY SNAPSHOT
TABLE 139. AGILENT: OPERATING SEGMENTS
TABLE 140. AGILENT: PRODUCT PORTFOLIO
TABLE 141. AGILENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 142. BGI: COMPANY SNAPSHOT
TABLE 143. BGI: OERATING SEGMENT
TABLE 144. BGI: PRODUCT PORTFOLIO
TABLE 145. BGI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 146. ROCHE: COMPANY SNAPSHOT
TABLE 147. ROCHE: OPERATING SEGMENTS
TABLE 148. ROCHE: PRODUCT PORTFOLIO
TABLE 149. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 150. ILLUMINA: COMPANY SNAPSHOT
TABLE 151. ILLUMINA: OERATING SEGMENT
TABLE 152. ILLUMINA: PRODUCT PORTFOLIO
TABLE 153. ILLUMINA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 154. PRECIGEN: COMPANY SNAPSHOT
TABLE 155. PRECIGEN: OPERATING SEGMENTS
TABLE 156. PRECIGEN: PRODUCT PORTFOLIO
TABLE 157. PACBIO: COMPANY SNAPSHOT
TABLE 158. PACBIO: OERATING SEGMENT
TABLE 159. PACBIO: PRODUCT PORTFOLIO
TABLE 160. PACBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 161. PERKINELMER: COMPANY SNAPSHOT
TABLE 162. PERKINELMER: OERATING SEGMENT
TABLE 163. PERKINELMER: PRODUCT PORTFOLIO
TABLE 164. PERKINELMER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 165. PIERIANDX: COMPANY SNAPSHOT
TABLE 166. PIERIANDX: PRODUCT PORTFOLIO
TABLE 167. PIERIANDX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 168. QIAGEN: COMPANY SNAPSHOT
TABLE 169. QIAGEN: OERATING SEGMENT
TABLE 170. QIAGEN: PRODUCT PORTFOLIO
TABLE 171. QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 172. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 173. THERMO FISHER SCIENTIFIC: OERATING SEGMENT
TABLE 174. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 175. THERMO FISHER SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTSLIST OF FIGURES
FIGURE 01. NEXT GENERATION SEQUENCING (NGS) MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2019-2020
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2020
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2019-2020
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. DNA FRAGMENTATION, END REPAIR, A-TAILING AND SIZE SELECTION MARKET, 2020-2030 ($MILLION)
FIGURE 14. LIBRARY PREPARATION & TARGET ENRICHMENT MARKET, 2020-2030 ($MILLION)
FIGURE 15. QUALITY CONTROL MARKET, 2020-2030 ($MILLION)
FIGURE 16. OTHER CONSUMABLES MARKET, 2020-2030 ($MILLION)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR CONSUMABLES,
BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. HISEQ SERIES PLATFORM MARKET, 2020-2030 ($MILLION)
FIGURE 19. MISEQ SERIES PLATFORM MARKET, 2020-2030 ($MILLION)
FIGURE 20. ION TORRENT PLATFORM MARKET, 2020-2030 ($MILLION)
FIGURE 21. SOLID PLATFORM MARKET, 2020-2030 ($MILLION)
FIGURE 22. PACBIO RS II AND SEQUEL SYSTEM MARKET, 2020-2030 ($MILLION)
FIGURE 23. OTHER SEQUENCING PLATFORMS MARKET, 2020-2030 ($MILLION)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR PLATFORM,
BY COUNTRY, 2020 & 2030 (%)
FIGURE 25. RNA SEQUENCING MARKET, 2020-2030 ($MILLION)
FIGURE 26. WHOLE EXOME SEQUENCING MARKET, 2020-2030 ($MILLION)
FIGURE 27. WHOLE GENOME SEQUENCING MARKET, 2020-2030 ($MILLION)
FIGURE 28. TARGETED SEQUENCING MARKET, 2020-2030 ($MILLION)
FIGURE 29. CHIP SEQUENCING MARKET, 2020-2030 ($MILLION)
FIGURE 30. DE NOVO SEQUENCING MARKET, 2020-2030 ($MILLION)
FIGURE 31. METHYL SEQUENCING MARKET, 2020-2030 ($MILLION)
FIGURE 32. NGS DATA ANALYSIS SERVICES MARKET, 2020-2030 ($MILLION)
FIGURE 33. NGS ANALYSIS SOFTWARE & WORKBENCHES MARKET, 2020-2030 ($MILLION)
FIGURE 34. NGS STORAGE, MANAGEMENT, AND CLOUD COMPUTING SOLUTIONS MARKET, 2020-2030 ($MILLION)
FIGURE 35. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR SERVICES,
BY COUNTRY, 2020 & 2030 (%)
FIGURE 36. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING FOR BIOMARKERS AND
CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 37. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS,
BY COUNTRY, 2020 & 2030 (%)
FIGURE 38. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR REPRODUCTIVE
HEALTH, BY COUNTRY, 2020 & 2030 (%)
FIGURE 39. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 40. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR AGRICULTURE
AND ANIMAL RESEARCH, BY COUNTRY, 2020 & 2030 (%)
FIGURE 41. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR OTHER
APPLICATIONS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 42. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING FOR SEQUENCING BY
SYNTHESIS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 43. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR ION
SEMICONDUCTOR SEQUENCING, BY COUNTRY, 2020 & 2030 (%)
FIGURE 44. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR SEQUENCING
BY LIGATION, BY COUNTRY, 2020 & 2030(%)
FIGURE 45. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR PYROSEQUENCING,
BY COUNTRY, 2020 & 2030(%)
FIGURE 46. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR SINGLE-MOLECULE-REAL-TIME SEQUENCING, BY COUNTRY, 2020 & 2030 (%)
FIGURE 47. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR OTHER
APPLICATIONS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 48. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR ACADEMIC &
CLINICAL RESEARCH CENTERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 49. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020& 2030 (%)
FIGURE 50. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR HOSPITALS &
CLINICS, BY COUNTRY, 2020& 2030 (%)
FIGURE 51. COMPARATIVE SHARE ANALYSIS OF NEXT-GENERATION SEQUENCING MARKET FOR OTHER END
USERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 52. AGILENT: NET SALES, 2018-2020 ($MILLION)
FIGURE 53. AGILENT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 54. AGILENT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 55. ROCHE: NET SALES, 2018-2020 ($MILLION)
FIGURE 56. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 57. ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 58. ILLUMINA: NET SALES, 2018-2020 ($MILLION)
FIGURE 59. ILLUMINA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 60. PRECIGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 61. PRECIGEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 62. PACBIO: NET SALES, 2018-2020 ($MILLION)
FIGURE 63. PACBIO: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 64. PERKINELMER: NET SALES, 2018-2020 ($MILLION)
FIGURE 65. PERKINELMER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 66. PERKINELMER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 67. QIAGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 68. QIAGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 69. THERMO FISHER SCIENTIFIC: NET SALES, 2018-2020 ($MILLION)
FIGURE 70. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 71. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2020 (%)
Companies Mentioned
- Agilent Technologies Inc.
- BGI Group
- F. Hoffmann-La Roche AG
- Illumina Inc
- Precigen Inc.
- (Intrexon Bioinformatics Germany GmbH)
- Pacific Biosciences of California Inc.
- PerkinElmer Inc.
- PierianDx Inc.
- Qiagen N.V.
- Thermo Fisher Scientific Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
